Reflux esophagitis: effect of oral bethanechol on symptoms and endoscopic findings.
We ascertained the effectiveness of oral bethanechol on symptoms and endoscopic evaluation of reflux esophagitis in a double-blind controlled study. Forty-four patients were treated with either 25-mg bethanechol tablets or placebo, each given four times daily for 4 weeks, in addition to conventional medical therapy. Both therapies significantly decreased symptoms as well as endoscopic lesions; however, endoscopic improvement was significantly better in the bethanechol-treated group. Bethanechol therapy resulted in complete endoscopic healing in 10 of 22 cases, whereas only three of 22 patients in the control group had such healing. No worsening of endoscopic lesions was seen in either group. Our study indicates that bethanechol is an effective drug offering advantages over conventional antacid therapy in the treatment of reflux esophagitis.
D000284:Administration, Oral; D001626:Bethanechol Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004942:Esophagitis, Peptic / Q000175:diagnosis / Q000188:drug therapy*; D004945:Esophagoscopy; D005260:Female; D005773:Gastroscopy; D006801:Humans; D008297:Male; D008365:Manometry; D008875:Middle Aged
D001626:Bethanechol Compounds